Researchers at IDWeek 2015 presented positive efficacy data for the grazoprevir/elbasvir (EBR/GZR) regimen for patients co-infected with hepatitis C virus (HCV) and HIV.
Live at IDWeek 2015
Once-daily single-tablet ledipasvir/sofosbuvir (LDV/SOF) provided high rates of sustained virologic response (SVR) at Week 12 in both patients with hepatitis C virus (HCV) mono-infection and HIV/HCV coinfection, according to results of a pooled analysis presented at IDWeek 2015.
Monthly intranasal mupirocin prophylaxis in the neonatal intensive care unit (NICU) dramatically decreased healthcare-associated transmission of methicillin-resistant Staphylococcus aureus (MRSA) infections by 43% and cut invasive staphylococcal infections by 73%, according to a study presented at IDWeek 2015.
Quadrivalent live attenuated influenza vaccine (LAIV4) was effective against B strains vs. no vaccine or trivalent/quadrivalent inactivated influenza vaccines (IIV3/4), but not against A/H3N2 strains during the 2014-2015 influenza season in children, results of a multicenter study presented at IDWeek 2015 have found.
Administering a three-Lactobacillus spp. probiotic to patients undergoing antibiotic therapy might reduce the frequency of nosocomial Clostridium difficile infections (CDI), suggest findings from a single-institution study reported at IDWeek 2015.
Renal impairment does not appear to affect the safety or clinical efficacy of tedizolid compared to linezolid among adults treated for skin and skin structure infections (ABSSSI), according to a post-hoc analysis of data from two randomized, controlled phase 3 clinical trials, reported at IDWeek 2015.
Patients with good prognoses suffer longer hospitalizations when they receive inappropriate empirical antimicrobial therapy for E. coli and other gram-negative bloodstream infections, according to study findings reported at IDWeek 2015.
High-dose oral vancomycin does not improve clinical outcomes over 125mg low dose vancomycin therapy among adult patients with nosocomial Clostridium difficile infection (CDI), according to retrospective study findings reported at IDWeek 2015
Opioid use was associated with an increased risk of hospitalizations for serious infections, and was higher with current use at higher daily doses and when using long-acting formulations, data from a case series analysis has shown at IDWeek 2015.
Treatment with boceprevir and pegylated interferon/ribavirin (PIFN/R) in persons co-infected with hepatitis C virus (HCV)and HIV resulted in higher sustained virologic response (SVR) rates at 12 weeks if they were treatment-naïve without cirrhosis, Phase 3 trial results reported at IDWeek 2015 have found.
Want to read more?
Please login or register first to view this content.